Clinical Trial Update: Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating imatinib mesylate in patients with advanced soft tissue sarcoma or bone sarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Sarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma | Phase 2 | Status: COMPLETED